- Report
- March 2024
- 189 Pages
Global
From €3242EUR$3,374USD£2,788GBP
€3602EUR$3,749USD£3,097GBP
- Report
- February 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,131GBP
- Report
- December 2023
- 200 Pages
Global
From €4804EUR$5,000USD£4,131GBP
- Report
- August 2023
- 180 Pages
Global
From €3603EUR$3,750USD£3,098GBP
- Report
- November 2023
- 185 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1922EUR$2,000USD£1,652GBP
- Drug Pipelines
- April 2024
- 50 Pages
Global
From €1441EUR$1,500USD£1,239GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1201EUR$1,250USD£1,033GBP
- Report
- November 2023
- 185 Pages
Global
From €4708EUR$4,900USD£4,048GBP
- Report
- March 2024
- 168 Pages
Global
€4799EUR$4,995USD£4,127GBP
- Report
- June 2021
- 675 Pages
Global
From €4084EUR$4,250USD£3,511GBP
- Report
- April 2020
- 67 Pages
Global
From €4756EUR$4,950USD£4,090GBP
- Report
- February 2023
- 164 Pages
Global
From €7206EUR$7,500USD£6,197GBP
- Report
- August 2022
- 119 Pages
Global
From €4324EUR$4,500USD£3,718GBP
- Report
- March 2023
- 69 Pages
Global
From €6716EUR$6,990USD£5,775GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,189GBP
- Report
- November 2021
- 620 Pages
Global
From €3843EUR$4,000USD£3,305GBP
- Report
- April 2023
- 147 Pages
Global
From €5764EUR$5,999USD£4,956GBP
Ribavirin is an antiviral drug used to treat a variety of infectious diseases, including hepatitis C, respiratory syncytial virus, and Lassa fever. It is a nucleoside analog, meaning it works by interfering with the replication of viral genetic material. Ribavirin is typically administered orally or intravenously, and is often used in combination with other antiviral drugs.
Ribavirin is a widely used drug in the infectious diseases market, and is often prescribed in combination with other antiviral drugs. It is generally well-tolerated, but can cause side effects such as anemia, fatigue, and nausea.
The market for ribavirin is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Mylan, Teva Pharmaceuticals, and Cipla. Other companies such as Dr. Reddy's Laboratories, Sun Pharmaceuticals, and Lupin also offer ribavirin products. Show Less Read more